Old Web
English
Sign In
Acemap
>
authorDetail
>
Sofie Berg
Sofie Berg
AbbVie
Crohn's disease
Randomization
Medicine
Abdominal pain
Risankizumab
3
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
OP36 Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
2021
Journal of Crohn's and Colitis
P Bossuyt
Marc Ferrante
F Baert
S. Danese
Brian G. Feagan
Edward V. Loftus
Julià Panés
Laurent Peyrin-Biroulet
Zhihua Ran
A. Armuzzi
G R D’Haens
A P Song
Ezequiel Neimark
Xiaomei Liao
Qian Zhou
Sofie Berg
Kori Wallace
Remo Panaccione
Show All
Source
Cite
Save
Citations (0)
DOP88 Effect of risankizumab on patient-reported outcomes in patients with Crohn’s Disease who had an inadequate response or intolerance to conventional and/or biologic treatments: Results from phase 3 MOTIVATE and ADVANCE trials
2021
Journal of Crohn's and Colitis
Laurent Peyrin-Biroulet
Edouard Louis
Subrata Ghosh
Scott D. Lee
J Griffith
Kori Wallace
Sofie Berg
Edward V. Loftus
Show All
Source
Cite
Save
Citations (0)
OP26 Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
2021
Journal of Crohn's and Colitis
S W Schreiber
Marc Ferrante
Remo Panaccione
J.-F. Colombel
Tadakazu Hisamatsu
A. Lim
James O. Lindsay
David T. Rubin
W. J. Sandborn
Ezequiel Neimark
A P Song
Xiaomei Liao
T Feng
Sofie Berg
Kori Wallace
G R D’Haens
Show All
Source
Cite
Save
Citations (0)
1